Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2022

Open Access 01-12-2022 | Crohn's Disease | Case report

Stelara struck: a case of noninfectious pneumonitis secondary to ustekinumab

Authors: Katherine A. Despotes, Christine L. Vigeland

Published in: BMC Pulmonary Medicine | Issue 1/2022

Login to get access

Abstract

Background

We describe a case of acute hypoxic respiratory failure due to drug induced lung disease secondary to ustekinumab, which is a monoclonal antibody used to treat psoriasis, psoriatic arthritis, and inflammatory bowel disease.

Case presentation

A 33-year-old man with a history of Crohn’s disease presented with fevers, myalgias, and abdominal pain, and subsequently developed acute hypoxemic respiratory failure approximately 2 weeks after restarting ustekinumab for his Crohn’s disease. Cross-sectional chest imaging showed ground glass opacities and bilateral consolidations. Due to progressive hypoxia, he ultimately required intubation and mechanical ventilation. Broad infectious and autoimmune work up was negative, making drug induced interstitial lung disease (DILD) the leading consideration. He was treated with high dose steroids with dramatic improvement in his respiratory status. At follow up, his imaging findings had largely resolved, and his pulmonary function tests were normal.

Conclusions

For patients presenting with acute hypoxic respiratory failure, it is critical to identify the underlying cause. In addition to testing for common respiratory infections that can cause respiratory failure, patients should also be evaluated for risk factors for developing atypical or opportunistic infections as well as inflammatory pneumonitis. Due to receiving ustekinumab, our patient was both at risk for developing an opportunistic infection as well as DILD. Although rare, DILD is a recognized toxicity of ustekinumab. Ustekinumab can cause significant lung injury, as in our patient, but with steroids and avoidance of future doses of the medication, our patient demonstrated good recovery. Reassuring outcomes have similarly been described in the literature; however, this case provides further details about outcomes with long-term follow-up clinical, imaging, and pulmonary function testing data available. We recommend consideration of high dose steroids for these patients for whom DILD is suspected.
Literature
1.
go back to reference Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23):2526–33.PubMed Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23):2526–33.PubMed
2.
go back to reference Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788–800.CrossRef Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788–800.CrossRef
3.
go back to reference Sime PJ, O’Reilly KM. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol. 2001;99(3):308–19.CrossRef Sime PJ, O’Reilly KM. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol. 2001;99(3):308–19.CrossRef
4.
go back to reference Skeoch S, Weatherley N, Swift A, Oldroyd A, Johns C, Hayton C, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med. 2018;7(10):356.CrossRef Skeoch S, Weatherley N, Swift A, Oldroyd A, Johns C, Hayton C, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med. 2018;7(10):356.CrossRef
5.
go back to reference Brinker A, Cheng C, Chan V. Association of noninfectious pneumonia with ustekinumab use. JAMA Dermatol. 2019;155(2):221–4.CrossRef Brinker A, Cheng C, Chan V. Association of noninfectious pneumonia with ustekinumab use. JAMA Dermatol. 2019;155(2):221–4.CrossRef
6.
go back to reference Kalra SS, Chizinga M, Trillo-Alvarez C, Papierniak ES. Ustekinumab associated chronic eosinophilic pneumonia. J Asthma. 2020;58(12):1670–4.CrossRef Kalra SS, Chizinga M, Trillo-Alvarez C, Papierniak ES. Ustekinumab associated chronic eosinophilic pneumonia. J Asthma. 2020;58(12):1670–4.CrossRef
7.
go back to reference Kikuchi S, Umezawa Y, Hayashi M, Yanaba K, Fukuchi O, Ito T, et al. Interstitial pneumonia in two patients with psoriasis during ustekinumab treatment. J Dermatol. 2016;43(6):712–3.CrossRef Kikuchi S, Umezawa Y, Hayashi M, Yanaba K, Fukuchi O, Ito T, et al. Interstitial pneumonia in two patients with psoriasis during ustekinumab treatment. J Dermatol. 2016;43(6):712–3.CrossRef
Metadata
Title
Stelara struck: a case of noninfectious pneumonitis secondary to ustekinumab
Authors
Katherine A. Despotes
Christine L. Vigeland
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2022
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-022-02066-z

Other articles of this Issue 1/2022

BMC Pulmonary Medicine 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.